James has been working on Photobiomodulation for 30 years (since 1987). He is a recognised authority on Photobiomodulation dose, dose rate effects and the measurement and reporting of parameters. He has written or co-authored 18 published academic papers and three books on Laser Photobiomodulation.
His most recent appointments include: Biomedical Optics Society conference chair (2009 – to-date), Fellow of The Royal Society of Medicine (2009 – to-date), Editorial Board of Photomedicine and Laser Surgery (2008 to-2015), and served on the World Association for Laser Therapy (2000 – 2004) and the North American Association for Laser Therapy (2002 – 2006). James presented Photobiomodulation to the United Nations Global Health Impact Forum, and is a recent recipient of the 2020 WALT (World Association for Laser Therapy) Presidential Commendation for service and Leadership in Photobiomodulation.
Hi, I was told by a PBM expert working with oncologic patients that B-cell malignancies, such as multiple myeloma, can be negatively affected by PBM. That PBM may stimulate progression of the malignancy. Have you seen any data, or do you have any experiences, supporting this claim? Are there good enough safety data available from treatment studies (eg from patients treated for mucositis/osteonecrosis, that make it possible to draw this conclusion? It would be great if you, or any of your colleagues, could let me know. I am interested in this question both of professional and personal reasons. My email is ivana.hollan@gmail.com. Thank you for the wonderful meeting and your presentations.